Business Wire

MFA Certifies First MulteFire Device and Base Station to Enable Private Networks in Unlicensed Spectrum

9.9.2021 17:43:00 EEST | Business Wire | Press release

Share

MFA, an international organization championing the global industry adoption of private networks, is gaining industry momentum with the recent certification of the Nokia Industrial MulteFire fieldrouter 700 and announcement of Uni5G Technology Blueprints. The Nokia MulteFire solution, which is available for deployment with Nokia Digital Automation Cloud, will enable MulteFire LTE-based private network adoption worldwide, unlocking access to unlicensed spectrum. With deployment available globally, it can be used by small and medium enterprises without access to licensed spectrum and it can bring additional capacity as a complementary layer to wireless networks and enable new nomadic use cases to advance Industry 4.0.

In addition to supporting 4.9G/LTE private networks, MFA recently announced its expansion to 5G with Uni5G Technology Blueprints, which help provide guidance to enterprises looking to deploy 5G private networks. MFA is also developing best practices and targeted guides to help industry verticals implement the key 3GPP 5G specification features that are relevant to their specific deployment.

The MFA Certification Program ensures that devices have implemented the MulteFire specifications correctly and are able to interoperate with devices from other manufacturers.

“The Nokia MulteFire solution has passed rigorous interoperability testing at our Authorized Test Lab DEKRA,” said Scott Fischel, MFA Certification Group Chair. “We congratulate Nokia on delivering the world’s first MulteFire Certified end-to-end solution that will provide end-users with confidence that it can meet the robust connectivity requirements offered by MulteFire 4.9G/LTE private wireless.”

“Private 5G and LTE networks are a rapidly growing market and will account for over $5B in global enterprise expenditure by 2025,” said Pablo Tomasi, Principal Analyst, Private Networks, Omdia. “MFA aims to support and accelerate the private 5G networks market through both this certification program and by tackling the issue of replicability and complexity through the delivery of Uni5G Technology Blueprints developed to simplify deployment for different industry verticals.”

The MFA Certification Program is available to MFA members, and it will help facilitate further expansion of the MulteFire private wireless ecosystem. For companies interested in joining the MFA, visit www.mfa-tech.org/become-a-member.

Resources:

About MFA

MFA is an international organization that is championing the global industry adoption of private networks using MFA-defined MulteFire specifications for LTE and Uni5G Technology Blueprints for 5G. With Uni5G or MulteFire, enterprises can efficiently deploy their own optimized, reliable and secure private network in unlicensed, shared or locally licensed spectrum. For more information, visit www.mfa-tech.org.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

MFA
Lori Mesecke, +1-503-459-9150
press@multefire.org

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Shilpa Medicare and Gate2Brain Sign Strategic Equity Partnership to Advance First-in-Class Brain Cancer Therapy8.6.2026 13:00:00 EEST | Press release

Shilpa Biocare Pvt Ltd, a Subsidiary of Shilpa Medicare Limited (BSE/NSE: SHILPAMED) has entered a strategic equity partnership with Gate2Brain, S.L., a biotechnology company focused on CNS therapeutics. Shilpa becomes a strategic shareholder and CMC, manufacturing, and regulatory partner for G2B-002 — Gate2Brain's lead program targeting deadly pediatric brain cancers, DIPG and pGBM, both with Orphan Drug Designation from the US FDA and EMA. G2B-002 uses Gate2Brain's proprietary MiniAp4 peptide shuttle to deliver SN-38 across the blood-brain barrier, demonstrating up to 100-fold greater brain drug transport preclinically. First-in-human trials are anticipated by FY28. G2B-002 targets high-growth oncology markets — the glioblastoma market projected at USD 6.48B by 2035 (CAGR: 7.97%), pediatric brain tumors at USD 2.47B by 2031 (CAGR: 6.9%), and DIPG at USD 1.2B by 2035 (CAGR: 7.1%). Gate2Brain's MiniAp4 platform further extends potential across rare pediatric cancers and broader CNS cat

Haleon Invests in India to Deliver Better Everyday Health to Rural Communities8.6.2026 12:11:00 EEST | Press release

Haleon, a consumer company that is solely focused on better everyday health, today announces plans to expand its business in India, one of its fastest-growing markets and key to Haleon delivering its strategy and ambitions to reach one billion more consumers by 2030. Haleon will invest approximately £175 million2 in building a new oral health manufacturing site in Madhya Pradesh, central India and accelerate distribution efforts in rural India to meet rising demand. The new site will also support supply for wider Asia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608753094/en/ Haleon Health Ambassador on motorbike, equipped with testing kits, samples and diagnostic tools Building capacity to meet rising demand The new site, which is well-positioned in the middle of the country and close to some of India’s most renowned technical colleges, marks an important step in the delivery of Haleon’s Win as One strategy. Win as On

Diabetology’s Breakthrough Clinical Data From Oraglutide™ Oral GLP-18.6.2026 11:56:00 EEST | Press release

Diabetology Limited (Jersey) poster presentation (https://diabetology.co.uk/ada-poster) 1724-P at the ADA 86th Scientific Session, New Orleans, reporting first human data from Oraglutide™ — small capsule intestinally-released oral semaglutide, formulated using the proprietary Axcess™ delivery technology. KEY HIGHLIGHTS 6-day glucose control: A single 4 mg oral dose of Oraglutide™ produced a sustained fall in glucose. Measuring 14% at Day 6 (p=.046), the longest duration presented from a single oral GLP-1 dose in a human IVGTT study. 28% increase in insulin secretion: Relative to placebo, insulin percent AUC increased by 12% day 0, (p=0.02) & 28% Day 1 (p = 0.025). Novel intestinal depot effect: Blood levels of semaglutide were higher on Day 1 than dosing on Day 0, consistent with lipid associated depot effect in the intestinal wall, a fundamentally new pharmacological finding. No nausea or side effects observed: No adverse events observed across the 8-subject cohort over one week, cons

Cardiolife Partners with Bhutan Ministry of Health to Strengthen Nationwide Cardiac Care8.6.2026 11:00:00 EEST | Press release

Cardiolife is proud to partner with the Ministry of Health of Bhutan to roll out its advanced AI-powered ECG diagnostics system nationwide. The collaboration will provide access to early ECG diagnosis and prevention, marking a major step forward in the country’s effort to strengthen heart health and preventive care. Bhutan has a population of just over 700,000 people and heart failure and other cardiac conditionsare among the leading causes of death. Following constructive meetings in Thimphu, His Excellency, the Health Minister, officially endorsed the national rollout of Cardiolife’s solution and expressed appreciation for Cardiolife’s commitment to advancing cardiac care through the provision of free software and ECG equipment in Bhutan. “We are grateful to the Cardiolife team for their commitment to improving heart health in Bhutan. With cardiovascular diseases on the rise, this collaboration marks an important milestone in our journey to strengthen early detection and prevention a

Reply at VivaTech 2026: Making AI, Agents and Robotics Happen Across the Enterprise8.6.2026 11:00:00 EEST | Press release

Reply[EXM, STAR: REY] is taking part in VivaTech 2026, Europe's largest innovation and technology event, held from June 17 to 20 at Paris Expo Porte de Versailles. At the event, Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608667672/en/ At VivaTech 2026 Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. Industries are being reshaped by AI, autonomous agents, robotics and new digital experiences. From strategy to execution, Reply helps companies move beyond experimentation and innovative ideas into concrete business value. Visitors can meet Reply in Hall 7.1, booth 1G12, and explore how, through real use cases, scalable solutions and live demonstrations, the group makes innovation happen. This year, Reply'

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye